Endocrine oncology (Bristol, England) · 2025
177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shekhda Kalyan Mansukhbhai, Armeni Eleni, Xu Yiwang, D'afflitto Manfredi, Hayes Aimee, Mandair Dalvinder, Yu Dominic, Quigley Ann-Marie, Navalkissoor Shaunak, Gnanasegaran Gopinath, Grossman Ashley B, Caplin Martyn, Toumpanakis Christos, Khoo Bernard
Аннотация
INTRODUCTION: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) represents a possible therapeutic option for patients with metastatic inoperable phaeochromocytomas (PCC) and paragangliomas (PGL) who demonstrate adequate somatostatin analogue binding on molecular imaging. We describe treatment outcomes in our cohort of patients stratified according to germline pathogenic variants (PV) in succinate dehydrogenase (SDHx) subunit-encoding genes.
METHODS: In this retrospective analysis, we evaluated 20 patients with metastatic PCC/PGL who underwent two or more cycles of 177Lu-DOTATATE therapy. Clinical, radiological, and biochemical responses were assessed 8-12 weeks after the final PRRT cycle. We describe overall treatment efficacy at follow-up after stratifying according to the presence of germline SDHx PV. Radiological progression was quantified based on the sum of the longest diameter (SLD) of the target lesion. Progression-free survival (PFS) and overall survival were estimated using Kaplan-Meier survival analysis. We also aimed to investigate the impact of PRRT on health-related quality of life (HRQoL), as assessed using the EORTC QLQ-GINET21 questionnaire.
RESULTS: After a median follow-up of 29 months, we confirmed stable disease in 12 patients (60%), a partial response in one (5%), and progressive disease in seven patients (35%). The absolute mean difference in SLD was +5 ± 12 mm for bone lesions, -4 ± 6 mm for peritoneal, +8 ± 14 mm for liver lesions and -1 ± 5 mm for lymph nodes (paired t-test P-value 0.273, 0.741, 0.208 and 0.826, respectively). Thirteen patients (65%) had received two or more previous lines of treatment. The overall median PFS for the entire cohort, PGL patients, SDHx positive and negative groups was 24 months (95% CI: 9.9-38.1), 18 months (95% CI: 8.4-27.6), 24 months (95% CI: 11.9-36.0) and 18 months (95% CI: 0-48), respectively. No grade 3/4 cytopenia or nephrotoxicity was observed. Overall, HRQoL improved after PRRT, as evidenced by the progressive decline in overall symptom scores in the QLQ-GINET21.
CONCLUSION: 177Lu-PRRT appears to be an effective therapy with a good safety profile for patients with metastatic PPGL. It also appears to improve HRQoL in patients with metastatic PPGL. Further studies are needed to explore the most effective treatment modalities in this group of patients and their sequencing.
METHODS: In this retrospective analysis, we evaluated 20 patients with metastatic PCC/PGL who underwent two or more cycles of 177Lu-DOTATATE therapy. Clinical, radiological, and biochemical responses were assessed 8-12 weeks after the final PRRT cycle. We describe overall treatment efficacy at follow-up after stratifying according to the presence of germline SDHx PV. Radiological progression was quantified based on the sum of the longest diameter (SLD) of the target lesion. Progression-free survival (PFS) and overall survival were estimated using Kaplan-Meier survival analysis. We also aimed to investigate the impact of PRRT on health-related quality of life (HRQoL), as assessed using the EORTC QLQ-GINET21 questionnaire.
RESULTS: After a median follow-up of 29 months, we confirmed stable disease in 12 patients (60%), a partial response in one (5%), and progressive disease in seven patients (35%). The absolute mean difference in SLD was +5 ± 12 mm for bone lesions, -4 ± 6 mm for peritoneal, +8 ± 14 mm for liver lesions and -1 ± 5 mm for lymph nodes (paired t-test P-value 0.273, 0.741, 0.208 and 0.826, respectively). Thirteen patients (65%) had received two or more previous lines of treatment. The overall median PFS for the entire cohort, PGL patients, SDHx positive and negative groups was 24 months (95% CI: 9.9-38.1), 18 months (95% CI: 8.4-27.6), 24 months (95% CI: 11.9-36.0) and 18 months (95% CI: 0-48), respectively. No grade 3/4 cytopenia or nephrotoxicity was observed. Overall, HRQoL improved after PRRT, as evidenced by the progressive decline in overall symptom scores in the QLQ-GINET21.
CONCLUSION: 177Lu-PRRT appears to be an effective therapy with a good safety profile for patients with metastatic PPGL. It also appears to improve HRQoL in patients with metastatic PPGL. Further studies are needed to explore the most effective treatment modalities in this group of patients and their sequencing.